IP Library Granted Patent US 10,501,535
Granted Patent B2
US 10,501,535 · App. 15/163,391 · Granted Dec 10, 2019

Antibody targeting stem cell factor

Inventors: Nicholas W. Lukacs (Brighton, MI); Steven L. Kunkel (Ann Arbor, MI); Cory Hogaboam (Ann Arbor, MI)
Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
C07K16/24C07K2317/52C07K2317/56
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,501,535
App. No.
15/163,391
Granted
Dec 10, 2019
Kind
B2
Abstract

Provided herein are methods, compositions, and uses relating to inhibitors of stem cell factor. For example, provided herein are antibodies targeting stem cell factor and methods for treating fibrotic and tissue remodeling diseases.

Claims (15)

1. An isolated recombinant monoclonal anti-stem cell factor (SCF) antibody comprising:

(a) a light chain variable domain comprising an amino acid sequence comprising:

(i) a first amino acid sequence comprising the CDR1 sequence provided by amino acids 42-53 of SEQ ID NO: 4;

a second amino acid sequence comprising the CDR2 sequence provided by amino acids 69-79 of SEQ ID NO: 4; and

(iii) a third amino acid sequence comprising the CDR3 sequence provided by amino acids 112-124 of SEQ ID NO: 4; and

(b) a heavy chain variable domain comprising an amino acid sequence comprising:

(i) a first amino acid sequence comprising the CDR1 sequence provided by amino acids 45-56 of SEQ ID NO: 2;

a second amino acid sequence comprising the CDR2 sequence provided by amino acids 71-86 of SEQ ID NO: 2; and

(iii) a third amino acid sequence comprising the CDR3 sequence provided by amino acids 119-123 of SEQ ID NO: 2.

2. The antibody of claim 1 , wherein the antibody is a humanized antibody.

3. The antibody of claim 1 , wherein the antibody is a chimeric antibody.

4. The antibody of claim 1 , wherein the antibody is monovalent and comprises an Fc region.

5. The antibody of claim 1 , wherein the antibody is bivalent or bispecific.

6. The antibody of claim 1 , wherein the antibody is an antibody fragment selected from the group consisting of a Fab, a Fab′-SH, an Fv, an scFv, and a (Fab′) 2 .

7. The antibody of claim 1 , wherein the antibody comprises a single Fab region linked to an Fc region.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 14, 2016
From: LUKACS, NICHOLAS W.; KUNKEL, STEVEN L.; HOGABOAM, CORY
To: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
Reel/Frame 039158/0269 →
Continuity (7)
Continuation 14328024 · Jul 10, 2014
Continuation In Part 15058918 · Mar 2, 2016
Division 13937852 · Jul 9, 2013
Division 13347459 · Jan 10, 2012
Provisional Application 61844728 · Jul 10, 2013
Provisional Application 61431246 · Jan 10, 2011
Related Publication 20160257742A1 · Sep 8, 2016
Cited By (1)
US 12,410,246